| |
TARGETED
THERAPIES
 |
|
In this educational symposium, a breast cancer oncologist will
present an overview of the current role of targeted therapies
used in the treatment of breast cancer and provide an update
on emerging clinical trial data expected to markedly influence
practice patterns. The focus will be on issues that affect nurses
most, such as agents they can expect to administer, and
dosing and scheduling modifications based on new data. The
latter half of the program will consist of an interactive workshop
in which an expert panel of breast cancer oncology nurses will
present and discuss model algorithms for assessing and
managing common toxicities specific to breast cancer targeted
therapies. An interactive question-and-answer activity will lead
participants through common toxicity management algorithms
and will help to identify barriers (i.e., institutional, personal,
cultural) to algorithm implementation. Strategies for overcoming
these barriers will be identified and discussed, ultimately
providing attendees with a working model for incorporating up-to-date standards into their routine nursing practices. Program
attendees will receive several side-effect assessment and
management clinical tools, as well as sample patient education
tools, to utilize in their individual clinical practices.
|
| |
|
|
 |
|
Targeted therapy is quickly changing the treatment paradigm of NSCLC. In this educational symposium, a physician key opinion leader will describe the current treatment landscape and the mechanisms of action of targeted therapies via a 3-D video animated presentation. The remainder of the program will focus on the treatment of four patients with NSCLC, all receiving different therapeutic regimens. Video vignettes of patients with NSCLC and their interactions with oncology nurses will highlight common treatment experiences and effective nursing management strategies to ensure optimal patient outcomes. Audience response technology will be used to elicit experiences of program attendees and stimulate practice-change discussions. Program attendees will receive several clinical tools for side-effect assessment and management as well as sample patient education tools to utilize in their clinical practices.
|
| |
|
|
 |
|
Targeting Angiogenesis in Solid Tumors: Novel Clinical Approaches
This case-based discussion program is intended for
oncology nurse practitioners and clinical nurse
specialists. Current research on appropriate systemic
treatment sequencing for metastatic colorectal cancer
(mCRC), treatment of the older adult with mCRC, and
the emerging role of neoadjuvant and adjuvant
chemotherapy for patients with resectable or potentially
resectable liver metastases will be highlighted. The
cases will be presented by national key opinion leaders
in colorectal cancer and audience response questions
will be used to stimulate discussions with APN
attendees regarding optimal patient care. Nurse
participants have submitted their own challenging cases
throughout the past 3 months which will be discussed
with colleagues and expert panelists.
October 2007
October 2008
1 hours 30 minutes
1.4 contact hours
Newsletter (HTML)
Newsletter (PDF)
Evalution/Test |
|
|
|
|
Multitargeted Agents for Therapeutically Challenging Tumors: An Introduction for Oncology Nurses
The emergence of multitargeted agents in oncology broadens the scope of targeted therapies for cancer patients. As these agents move into the arena of approved therapies, oncology nurses must understand their mechanisms of action, administration guidelines, potential toxicities, and how to provide adequate education to patients receiving them. In this educational program, recent clinical data on the incorporation of multitargeted agents into the treatment of two therapeutically challenging tumor types, gastrointestinal stromal tumor and renal cell carcinoma, will be presented along with information on the nursing management of patients receiving these novel agents.
|
| |
|
|
|
|
The efficacy of conventional therapies for advanced head
and neck cancers is limited and has reached a plateau.
EGFR inhibitors are emerging as promising therapeutic
options for this group of diseases. In this educational
activity, advancements in the treatment of head and neck
cancers with EGFR inhibitors and the rationale for the use
of these agents will be discussed. Nursing management of
potential side effects and key aspects of patient education
will be highlighted.
|
| |
|
|
 |
|
Expanding Nursing Expertise in Targeted Therapy
This program will be the first of its kind for oncology nurses; the science behind targeted therapies will be presented in an animated format. The use of original 3-dimensional videos illustrating the cellular processes underlying tumor development and the mechanisms of action of targeted therapies will boost nurses’ current knowledge of these concepts. Nurses will also gain an enhanced understanding of why targeted agents are associated with specific toxicities and how targeted therapy differs from chemotherapy. Current and future clinical applications of targeted therapy will also be discussed. This symposium will challenge oncology nurses’ understanding of targeted therapies and help better prepare them for 21st century cancer care.
|
|
|
|
